


ROUTINE ATTRIBUTE MONITORING OF RNA: ENABLED DECISIONS FOR CONSISTENT PRODUCT QUALITY

Characterization and monitoring of critical quality attributes with harmonized workflows across the product lifecycle

LEARN MORE
[waters.com/CGT](https://www.waters.com/CGT)



EFFICIENCY

Fit for purpose systems and workflows for development, clinical and commercial operations

COMPLIANCE-READY

In built data integrity and qualification packages for regulated laboratories

STREAMLINED ONBOARDING

Robust, reliable and scalable solutions for simplified implementation



WORKFLOW DRIVEN

Purposely designed apps to automate data acquisition, processing and reporting

OPTIMIZED COLLABORATION


Networkable solutions to share data and methods with enhanced fidelity

Nucleic acid sequences can be delivered to initiate a diverse range of gene-based therapies and vaccine treatments. This includes gene silencing/modulation (oligonucleotide-based drugs), genetic therapies, gene modified cell therapies, DNA/RNA vaccines, and targeted gene editing.

These large, complex modalities require compliance-ready analytical techniques for characterization and chemistry, manufacturing, and control (CMC) monitoring, but manual, error-prone, and laborious workflows often challenge companies evolving these into routine CQA assays.

Waters brings industry-leading expertise, providing the analytical tools needed to support the development and commercialization of these exciting new modalities.

Integrated Analytical Solutions for Faster and Cost-effective Analysis of 5' Capping, 3' Poly(A) Tail Heterogeneity, Fragment Mapping and Lipid Nanoparticle Composition



RNA Workflows from Sample to Result

